210 related articles for article (PubMed ID: 20866164)
1. Outcomes of a rheumatoid arthritis disease therapy management program focusing on medication adherence.
Stockl KM; Shin JS; Lew HC; Zakharyan A; Harada AS; Solow BK; Curtis BS
J Manag Care Pharm; 2010 Oct; 16(8):593-604. PubMed ID: 20866164
[TBL] [Abstract][Full Text] [Related]
2. Improving patient self-management of multiple sclerosis through a disease therapy management program.
Stockl KM; Shin JS; Gong S; Harada AS; Solow BK; Lew HC
Am J Manag Care; 2010 Feb; 16(2):139-44. PubMed ID: 20148619
[TBL] [Abstract][Full Text] [Related]
3. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS.
Hirsch JD; Gonzales M; Rosenquist A; Miller TA; Gilmer TP; Best BM
J Manag Care Pharm; 2011 Apr; 17(3):213-23. PubMed ID: 21434698
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries.
Hirsch JD; Rosenquist A; Best BM; Miller TA; Gilmer TP
J Manag Care Pharm; 2009; 15(1):32-41. PubMed ID: 19125548
[TBL] [Abstract][Full Text] [Related]
6. Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy.
Peter ME; Zuckerman AD; DeClercq J; Choi L; James C; Cooper K; Choi J; Nadler M; Tanner SB
J Manag Care Spec Pharm; 2021 Jul; 27(7):882-890. PubMed ID: 34185565
[No Abstract] [Full Text] [Related]
7. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
Bergman M; Tundia N; Martin N; Suboticki JL; Patel J; Goldschmidt D; Song Y; Wright GC
Arthritis Res Ther; 2022 Jun; 24(1):155. PubMed ID: 35751108
[TBL] [Abstract][Full Text] [Related]
8. Primary medication nonadherence rates to specialty disease-modifying antirheumatic drugs for rheumatoid arthritis within a health system specialty pharmacy.
Petry L; Zuckerman AD; DeClercq J; Choi L; Lynch B; Saknini M
J Manag Care Spec Pharm; 2023 Jul; 29(7):732-739. PubMed ID: 37404072
[No Abstract] [Full Text] [Related]
9. Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases.
Bhattacharya R; Herren K; Poonawalla I; Bunniran S; Bloomfield A; Schwab P
J Manag Care Spec Pharm; 2020 Oct; 26(10):1246-1256. PubMed ID: 32996385
[TBL] [Abstract][Full Text] [Related]
10. Managing specialty medication services through a specialty pharmacy program: the case of oral renal transplant immunosuppressant medications.
Tschida S; Aslam S; Khan TT; Sahli B; Shrank WH; Lal LS
J Manag Care Pharm; 2013; 19(1):26-41. PubMed ID: 23383705
[TBL] [Abstract][Full Text] [Related]
11. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
12. Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
Tanaka Y; Takeuchi T; Izutsu H; Kaneko Y; Kato D; Fukuda M; Rokuda M; Schultz NM
Arthritis Res Ther; 2021 Aug; 23(1):221. PubMed ID: 34429152
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
[TBL] [Abstract][Full Text] [Related]
14. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
[TBL] [Abstract][Full Text] [Related]
15. Adherence, Persistence, and Expenditures for High-Cost Anti-Inflammatory Drugs in Rheumatoid Arthritis: An Exploratory Study.
Khilfeh I; Guyette E; Watkins J; Danielson D; Gross D; Yeung K
J Manag Care Spec Pharm; 2019 Apr; 25(4):461-467. PubMed ID: 30917076
[TBL] [Abstract][Full Text] [Related]
16. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.
Schiff MH; Yu EB; Weinblatt ME; Moreland LW; Genovese MC; White B; Singh A; Chon Y; Woolley JM
Drugs Aging; 2006; 23(2):167-78. PubMed ID: 16536638
[TBL] [Abstract][Full Text] [Related]
17. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
Bingham CO; Walker D; Nash P; Lee SJ; Ye L; Hu H; Khalid JM; Combe B
Arthritis Res Ther; 2022 Jan; 24(1):11. PubMed ID: 34980223
[TBL] [Abstract][Full Text] [Related]
18. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.
Strand V; Schiff M; Tundia N; Friedman A; Meerwein S; Pangan A; Ganguli A; Fuldeore M; Song Y; Pope J
Arthritis Res Ther; 2019 Dec; 21(1):263. PubMed ID: 31791386
[TBL] [Abstract][Full Text] [Related]
19. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA).
Osterhaus JT; Purcaru O; Richard L
Arthritis Res Ther; 2009; 11(3):R73. PubMed ID: 19457255
[TBL] [Abstract][Full Text] [Related]
20. Development of a process to improve medication adherence in patients with rheumatoid arthritis in the specialty pharmacy setting.
Amado AY; Frye C; Holland W; Holland CR; Rhodes LA; Marciniak MW
J Am Pharm Assoc (2003); 2020; 60(3S):S61-S64.e1. PubMed ID: 32446651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
